They probably tried to acquire Cytodyn but ran into two problems. The first being that NP had triple digits in mind from the get go, setting unrealistic expectations for anyone inquiring. And the other issue is anyone who looked into the data likely saw red flags thanks to Amarex, essentially decreasing the attractiveness of Cytodyn because the path to approval was going to be longer than originally seemed. All while NP held firm to extremely high valuations.

I’m glad he never helped push through a shitty offer, but I’m guessing it was a “word on the street” sort of thing where the combo of issues was a known problem for anyone interested.

Just a wild ass guess.